静脉静脉复原:发生率,机制和治疗选择
Michael Sola1, Zachary Tugaoen1, Jessica Willis1
1Division of Cardiology, University of North Carolina, Chapel Hill, NC, 27599-7075, USA.
Current cardiology reports
|June 19, 2025
概括
帕克利塔塞尔药物涂层气球和药物释放支架有效治疗支架内静止症 (ISR). 血管内成像指导治疗选择这一具有挑战性的条件,新的技术正在研究.
科学领域:
- 心血管医学 心血管医学
- 干预心脏病学 干预心脏病学
- 生物材料科学 生物材料科学
背景情况:
- 干预性心脏病学中,静脉静脉复缩 (ISR) 仍然是一个重大挑战.
- 尽管支架技术取得了进步,但先前植入的支架内的缩需要有效的治疗策略.
研究的目的:
- 审查目前对静脉静脉复缩 (ISR) 的治疗方法.
- 突出最近的技术进步及其对ISR管理的临床影响.
主要方法:
- 审查当前关于静脉静脉复缩治疗的文献.
- 药物涂层气球和药物排泄支架的疗效分析.
- 强调血管内成像在指导治疗决策中的作用.
主要成果:
- 帕克利塔塞尔药物涂层气球和第二代药物排泄支架在治疗ISR方面表现出相似的有效性.
- 用sirolimus涂层的气球代表了一个新兴的选择,需要进一步研究.
- 血管内成像对于诊断ISR机制和个性化治疗至关重要.
结论:
- 即使使用先进的支架世代,ISR的管理仍然很复杂.
- 帕克利塔塞尔药物涂层气球为ISR提供了一个无金属的治疗选择.
- 目前正在进行的研究正在评估新药涂层及其与帕克利塔塞尔相比的有效性.
相关概念视频
Peripheral Artery Disease III: Interprofessional Care
34
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
34
Coronary Artery Disease V: Interprofessional Care
39
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
39
Angina IV: Management
31
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
31
Atherosclerosis III: Management
42
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
42
Acute Coronary Syndrome IV: Interprofessional Care
32
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
32
Angina II: Classification
44
Angina, also known as angina pectoris, is a chest pain resulting from diminished blood flow to the heart muscle and is often a symptom of coronary artery disease. Angina presents several variants with distinctive attributes, etiologies, and therapeutic approaches. The main types of angina include stable, unstable, variant (Prinzmetal's), microvascular, intractable, and silent ischemia.Stable angina is caused by atherosclerosis, which leads to the formation of plaques that narrow the coronary...
44


